Yousif Capital Management LLC Grows Stock Holdings in Becton, Dickinson and Company $BDX

Yousif Capital Management LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,913 shares of the medical instruments supplier’s stock after purchasing an additional 1,260 shares during the period. Yousif Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $11,353,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GQG Partners LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth about $689,833,000. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the period. Nuveen LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth about $211,097,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Becton, Dickinson and Company in the second quarter worth about $155,080,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after buying an additional 667,957 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $186.76 on Tuesday. The stock’s 50 day simple moving average is $190.23 and its two-hundred day simple moving average is $185.45. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a market cap of $53.53 billion, a price-to-earnings ratio of 33.59, a PEG ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on BDX shares. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada assumed coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 target price on the stock. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler restated a “neutral” rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.